HELP

Cybin Inc. Common Stock NASDAQ Listed Sep 13, 2019

Healthcare ·Biotechnology ·CA · cybin.com

$5.36

Mkt Cap $267.2M

52w Low $4.29 19.2% of range 52w High $9.83

50d MA $5.47 200d MA $6.42

P/E (TTM) -8.4x

EV/EBITDA -0.3x

P/B 0.4x

Debt/Equity 0.0x

ROE —

P/FCF -1.7x

RSI (14) —

ATR (14) —

Beta 1.04

50d MA $5.47

200d MA $6.42

Avg Volume 1.1M

Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder

SIC Code

2834

CIK (SEC)

1833141

Phone

908 764 8385

100 King Street West · Toronto, ON M5X 1C9 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 16, 2026	AMC	-0.76	-0.99	-30.5%	—	—	—	—	—	—	—	—
Feb 13, 2026	AMC	-0.53	-0.72	-35.8%	6.09	+5.1%	+11.0%	+16.6%	+13.3%	+11.8%	+10.5%	—
Nov 13, 2025	AMC	-0.74	-1.39	-87.8%	—	—	—	—	—	—	—	—
Aug 13, 2025	AMC	-0.96	-1.10	-14.7%	—	—	—	—	—	—	—	—
Nov 13, 2024	AMC	-0.98	-2.86	-190.9%	—	—	—	—	—	—	—	—
Aug 8, 2024	AMC	-0.97	-0.12	+88.0%	—	—	—	—	—	—	—	—
Mar 31, 2024	AMC	—	-0.17	—	—	—	—	—	—	—	—	—
Feb 14, 2024	AMC	-1.22	-0.24	+80.5%	—	—	—	—	—	—	—	—
Nov 15, 2023	AMC	—	-0.05	—	—	—	—	—	—	—	—	—
Aug 14, 2023	AMC	—	-0.06	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.07	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.35	$7.15	-2.7%	+3.5%	+7.5%	+16.1%	-23.3%	-28.6%
Dec 3	Guggenheim	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Nov 20	Canaccord Genuity	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—

Data updated apr 25, 2026 1:18pm · Source: massive.com